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Abstract 
Growth arrest-specific gene (Gas) 6 is a Gla domain-containing protein which shares 
43% amino acid identity with protein S. Gas6 has been shown to enhance cancer cell 
proliferation in vitro. On the other hand, recent studies have demonstrated that Gas6 
inhibits Toll-like receptor-mediated immune reactions. Immune reactions are known to 
affect intestinal tumorigenesis. In this study, we investigated how Gas6 contributes to 
tumorigenesis in the intestine. Administration of recombinant Gas6 weakly, but 
significantly, enhanced proliferation of intestinal cancer cells (SW480 and HT29), while 
it suppressed the inflammatory responses of LPS-stimulated monocytes (THP-1). 
Compared with Gas6+/+ mice, Gas6–/– mice exhibited enhanced azoxymethane/dextran 
sulfate sodium (DSS)-induced tumorigenesis and had a shorter survival. Gas6–/– mice 
also exhibited more severe DSS-induced colitis. DSS-treated Gas6–/– mice showed 
attenuated Socs1/3 mRNA expression and enhanced NFB activation in the colonic 
stroma, suggesting that the target of Gas6 is stromal cells. Bone marrow transplantation 
experiments indicated that both epithelial cells and bone marrow-derived cells are Gas6 
sources. Furthermore, the number of intestinal tumors in ApcMin Gas6–/– mice was 
higher than that in ApcMin Gas6+/+ mice, resulting in shorter survival. In a group of 62 
patients with advanced colorectal cancer, Gas6 immunoreactivity in cancer tissues was 
positively correlated with prognosis. Thus, we revealed a unique in vivo inhibitory role 
of Gas6 during the progression of intestinal tumors associated with suppression of 
stromal immune reactions. These results suggest a novel therapeutic approach for 
colorectal cancer patients by regulation of stromal immune responses.
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Introduction 
 Colorectal cancer is one of the most common cancers in the world. To discover novel 
therapeutic strategies, the mechanisms of colorectal cancer development should be 
understood. In contrast to other cancers, colorectal cancer develops in a unique organ 
that harbors a vast population of microbes [1]. Accumulating evidence has indicated a 
crucial role of Toll-like receptor (TLR) signaling in the interaction between luminal 
microbes and intestinal tumorigenesis [2-4]. 
 TAM tyrosine kinase receptors (Tyro3, Axl, and Mer) exert pleiotropic effects [5]. 
Recent studies have shown that TAM receptors inhibit TLR-mediated inflammatory 
responses in dendritic cells and macrophages [5, 6]. Tyro3–/–Axl–/–Mer–/– triple knockout 
mice exhibit a broad spectrum of autoimmune diseases [7]. TAM receptors share two 
humoral ligands: protein S and growth arrest-specific gene 6 (Gas6) [8, 9]. Protein S is 
a well-defined vitamin-K-dependent plasma glycoprotein that serves as a cofactor of 
protein C in the inactivation of Factor Va and VIIIa in the anti-coagulation pathway. 
Gas6 is a -carboxyglutamic acid (Gla) domain-containing protein that was originally 
described in growth-arrested fibroblasts [10, 11]. Gas6 has the same domain 
organization as, and 43% amino acid identity with, protein S, and has the potential to 
induce platelet-mediated thrombosis. Both protein S and Gas6 effectively inhibit 
TLR-induced cytokine production in mouse dendritic cells and macrophages [5, 6, 12, 
13]. For example, TAM activation by Gas6 inhibits production of inflammatory 
cytokines, such as TNF-, induced by TLR3, 4, and 9 [6]. Taken together with the 
recent findings regarding the role of innate immunity in intestinal tumorigenesis [2-4], it 
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may be beneficial to investigate the potential involvement of TAM receptors and their 
ligands in intestinal tumor progression. 
 Among TAM receptors and two ligands, Axl and Gas6 have been particularly focused 
on in the field of tumor biology. Axl is associated with clinical outcome of leukemia, 
melanoma, and lung, prostate, ovarian, renal, thyroid, and gastric cancers [14-18]. Axl 
has transforming effects on human cancer cell lines [19, 20]. In contrast, although 
several reports have demonstrated the role of Gas6 in tumorigenesis by using cancer 
cell lines [15, 16, 21], the in vivo role of Gas6 in mouse tumor development or human 
colorectal cancer progression remains to be elucidated. 
 In this study, we sought to investigate the role of Gas6 during tumorigenesis in in vivo 
intestines using Gas6+/+ and Gas6–/– mice. 
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Materials & Methods 
Cell culture and reagents 
 Human colorectal cancer cell lines (SW480 and HT29) and a human macrophage cell 
line (THP-1) were obtained from the American Type Culture Collection (Manassas, VA, 
USA). Cell lines were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA, USA), 
supplemented with 10% fetal calf serum (FCS). Recombinant human Gas6, a 
-glutamyl carboxylated active form, was purchased from R&D Systems (Minneapolis, 
MN, USA). 
 
Cell proliferation assay 
 SW480 and HT29 cells were seeded at a density of 2.5  103 per well in 96-well tissue 
culture plates; after 24 hours, the medium was changed to FCS-free medium. After 
24-hour incubation under the indicated conditions, cell proliferations were measured 
using the MTS assay (Cell Counting Kit 8; Dojindo, Kumamoto, Japan) according to 
the manufacturer’s protocol. 
 
Animal model of colitis and intestinal tumorigenesis 
 Generation of Gas6 knockout mouse with a C57/BL6 background was described 
previously [22]. ApcMin mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA). Animals were housed under specific pathogen-free conditions at the Animal 
Facilities of Kyoto University. All animal experiments were performed in accordance 
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with institutional guidelines, and the Review Board of Kyoto University granted an 
ethical permission for this study. Isolations of mouse epithelial cells and stromal 
monocytes were described previously [23]. To analyze colitis-associated tumorigenesis, 
mice were injected with a single intraperitoneal dose of azoxymethane (AOM) (12 
mg/kg body weight; Sigma, St. Louis, MO, USA) at the age of 8 weeks and received 
2.0% dextran sulfate sodium (DSS) for 5 days 3 times every 3 weeks (Supplementary 
Figure 1A). To analyze the severity of colitis, mice were sacrificed after the 
administration of 2.5% DSS for 7 days (Supplementary Figure 1B). 
 
Real-time quantitative reverse- transcription polymerase chain reaction (qRT-PCR) 
 Total RNA was extracted using Trizol (Invitrogen). Single-strand complementary DNA 
(cDNA) was synthesized using Transcriptor First Strand cDNA Synthesis Kit (Roche 
Applied Science, Basel, Switzerland). qRT-PCR was performed using SYBR Green I 
Master (Roche Applied Science) and Light Cycler 480 (Roche Applied Science). Values 
are expressed as arbitrary units relative to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Primer sets used are summarized in Supplementary Table 1. 
 
Generation of bone marrow chimeric mice 
 Cell suspensions from male Gas6+/+ and Gas6–/– mouse bone marrow were prepared 
from femurs and tibias, filtered, and counted. Female or male mice received a single 
intravenous injection of 1 × 107 bone marrow cells, after being lethally irradiated with 
10 Gy X-rays. The following groups of chimeric mice were generated: Gas6+/+ to 
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Gas6+/+, Gas6+/+ to Gas6–/–, Gas6–/– to Gas6+/+, Gas6–/– to Gas6–/– mice. Genomic 
DNA was extracted from blood 4 weeks later, and bone marrow chimerism was 
determined by PCR for the Gas6 and Y chromosome–linked Sry genes. 
 
Histological and immunohistochemical analyses 
 Mouse intestinal tissues were routinely processed. Anti-Tyro3, Axl, Mer, ß-actin, and 
phosphorylated p65 (Cell Signaling Technology, Danvers, MA, USA), anti-Gr1 
(eBioscience, San Diego, CA, USA), anti-F4/80, Socs3, CD45, and TNF- (Abcam, 
Cambridge, MA, USA), and anti-Gas6 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) antibodies were used. The primary antibodies were incubated at 4°C overnight, 
and then secondary antibodies were added. All immunohistochemical analyses were 
performed with Ig isotype controls or blocking peptides for antibodies. 
 
Enzyme-linked immunosorbent assay 
 Nuclear protein was extracted from mouse intestinal tissues by using Nuclear Extract 
Kit (Active Motif, Carlsbad, CA, USA). Protein concentration was measured using 
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). DNA binding 
activity of p65 protein was quantified using TransAM NFB p65 Transcriptional ELISA 
Kit (Active Motif). 
 
Clinical sample analysis 
 Surgically resected specimens were obtained from Stage III/IV colorectal cancer 
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patients who had been admitted to Kyoto University Hospital. Written informed consent 
was obtained from all patients with the protocol approved by the Ethics Committee of 
Kyoto University. Patient’s data were anonymously analyzed, and neither the patient nor 
anyone else could identify the patient with certainty. Sixty-two surgically resected 
specimens were routinely processed and immunostained. Clinicopathological 
parameters of those patients are summarized in Supplementary Table 2. Gas6 staining in 
human cancer specimens was determined to be ‘high’ when ≥ 50% of the tumor cells 
were stained with anti-Gas6 antibody and to be ‘low’ when < 50% of the tumor cells 
were stained with anti-Gas6 antibody. The number of infiltrating CD45-positive 
leukocytes was counted in randomly selected 3 high power fields (× 400) in each 
specimen, and the mean number was determined. 
 
Statistical analysis 
 Results are presented as the mean values ± standard deviations unless otherwise stated. 
Difference between treatment, group, and strains were analyzed using the two-tailed 
Student’s t test, chi-square test, Fisher's exact test, ANOVA, and Bonferroni’s test. 






Gas6 enhanced the proliferation of colorectal cancer cells and suppressed the 
activation of macrophages in vitro 
 Previous reports using cancer cell lines have suggested that Gas6 contributes to tumor 
progression [15, 16, 21]. First, we examined the effects of Gas6 on epithelial cells and 
macrophages in vitro. The human colorectal cancer epithelial cell lines, SW480 and 
HT29 cells, were cultured for 24 hours in serum-free medium containing vitamin K (0.5 
µM) with or without recombinant human Gas6 protein (0.5 or 5.0 nM). Both cell lines 
expressed TAM receptors (Figure 1A), and MTS assays showed that the addition of 
Gas6 protein weakly, but significantly, enhanced the proliferation of both cell lines 
(Figure 1B). In addition, mRNA expression of inflammatory cytokines, such as TNF- 
and IL-8, were not altered after stimulation with LPS in SW480 and HT29 cells (100 
ng/ml; data not shown). Administration of LPS to THP-1 cells, a human macrophage 
cell line strongly expressing TAM receptors (Figure 1A), pretreated with 100 nM 
phorbol-12-myristate-13-acetate (PMA) induced the mRNA expression of inflammatory 
cytokines such as TNF- and IL-8 2 hours after LPS stimulation (Figure 1C). However, 
the simultaneous administration of 0.5 nM human Gas6 significantly reduced 
LPS-induced mRNA expression of TNF- and IL-8. In addition, the mRNA expression 
of SOCS1/3 was significantly enhanced in PMA/LPS-stimulated THP-1 cells after 
incubation with 0.5 nM recombinant Gas6 for 2 hours (Figure 1D). Concomitantly, 
immunocytochemistry showed that the nuclear accumulation of phosphorylated-p65 in 
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PMA/LPS-stimulated THP-1 cells was significantly reduced at 2 hours after incubation 
with 0.5 nM recombinant Gas6 (Figure 1E and F). Thus, Gas6 has an in vitro potential 
to promote the proliferation of colon cancer cells and to suppress the activation of 
immune responses in macrophages. 
 
Gas6 deficiency enhanced mouse colitis-associated tumorigenesis 
 Next, we investigated whether Gas6 affects mouse colitis-associated tumorigenesis. 
Under physiological conditions, the status of epithelial cells, stromal infiltration by 
inflammatory cells, and mRNA expression of TAM receptors were not altered in 
relation to the Gas6 gene dosage (data not shown). However, after 
azoxymethane/dextran sulfate sodium (AOM/DSS) treatment (Supplementary Figure 
1A), the number of polyps in the Gas6–/– mouse colon was significantly greater than that 
in the Gas6+/+ mouse colon (Figure 2A and B). Consistent with this, mRNA expression 
of proliferation cell nuclear antigen (PCNA) in the colonic polyps of the Gas6–/– mice 
was significantly higher than that in the polyps of the Gas6+/+ mice (Figure 2C). 
Infiltration of neutrophils and macrophages into colonic polyps of the Gas6–/– mice was 
more prominent (Figure 2D). In addition, mRNA expression of inflammatory cytokines, 
such as TNF-, CXCL1, and CCL2 was significantly upregulated in the colonic polyps 
of the Gas6–/– mice (Figure 2E). NFB was also significantly activated 
(phosphorylation of p65) in the colonic polyps of the Gas6–/– mice (Figure 2F). The 
mRNA expression of representative tumor-promoting factors, such as c-Myc and Cox2 
(Ptgs2), was significantly upregulated in the colonic polyps of the Gas6–/– mice (Figure 
 11 
2G). After AOM/DSS treatment, survival of the Gas6–/– mice was significantly shorter 
than that of the Gas6+/+ mice (P < 0.01; Figure 2H). Thus, contrary to in vitro studies, 
Gas6 played an inhibitory role in colitis-associated tumorigenesis in mice. 
 
Gas6 was increased locally and appeared to suppress immune responses of 
infiltrating stromal cells in DSS-induced mouse colitis 
 Persistent colitis is a risk factor for the progression of colonic tumors [24, 25]. 
Therefore, it would be possible in the AOM/DSS-treated Gas6–/– mice that 
inflammatory responses in the stromal cells (e.g., macrophages) played a pivotal role in 
enhancing polyp formation. To confirm whether Gas6 inhibits mouse colitis in vivo, we 
administered DSS to the Gas6+/+ and Gas6–/– mice (Supplementary Figure 1B). 
 After administration of 2.5 % DSS for 7 days, the Gas6–/– mice exhibited more severe 
colitis than the Gas6+/+ mice. In the Gas6–/– mice, the colonic crypt architecture was 
almost completely obliterated, with massive stromal infiltration by inflammatory cells, 
whereas in the Gas6+/+ mice the crypt architecture was relatively preserved (Figure 3A). 
The histological damage score [26] and weight loss of the DSS-treated Gas6–/– mice 
were significantly greater than those of the DSS-treated Gas6+/+ mice (Figure 3B). 
Stromal infiltration by neutrophils and macrophages was more prominent in the 
DSS-treated Gas6–/– mice (Figure 3C). Similarly, mRNA expression of TNF- CXCL1, 
and CCL2 was significantly higher in the DSS-treated Gas6–/– mice (Figure 3D). Thus, 
Gas6 had inhibitory activity in mouse colonic inflammation in the DSS-treated mice as 
well as in AOM/DSS-treated mice. 
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 In the DSS-treated Gas6+/+ mouse colon, Gas6 mRNA expression was significantly 
increased (Figure 4A), suggesting that locally produced Gas6 plays a role in 
DSS-induced colitis. Therefore, we sought to evaluate the in vivo activation of targets of 
Gas6/TAM. The mRNA expression of Socs1/3, which are key mediators of Gas6/TAM 
signaling in the downregulation of TLR-mediated immune responses of macrophages 
[6], was significantly lower in the DSS-treated Gas6–/– mouse colon than in the 
DSS-treated Gas6+/+ mouse colon (Figure 4A). ELISA showed that the phosphorylation 
level of nuclear p65, which is the downstream of TLRs and can be downregulated by 
Gas6/TAM signaling in macrophages [6], increased significantly in the DSS-treated 
Gas6–/– mice (Figure 4B). Thus, we confirmed that the activation of TLR/Gas6/TAM 
signaling in DSS-induced colitis was altered according to the Gas6 genotype. 
 We next performed immunostainings to determine the cell types in which these 
downstream molecules of Gas6/TAM signaling were activated. Stainings for Socs3 and 
phosphorylated-p65 were only partially observed in the non-inflamed Gas6+/+ and 
Gas6–/– mouse colons (Figure 4C, ascending, arrowheads). In contrast, Socs3 and 
phosphorylated-p65 were vigorously observed in mononuclear cells infiltrating the 
stroma especially in the inflamed part of the Gas6–/– mouse colon (Figure 4C, rectum). 
Because mRNA expression of TAM receptors in stromal monocytes were slightly 
higher than those in epithelial cells (data not shown), these results suggest that locally 
increased levels of Gas6 suppresses innate immune responses in DSS-induced colitis by 
upregulation of Socs1/3 and downregulation of NFB in infiltrating stromal cells. 
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Gas6 from both epithelial cells and bone marrow (BM)-derived cells contributed to 
suppression of DSS-induced mouse colitis 
 Previous reports have demonstrated that Gas6 is secreted by various cell types, such as 
tumor cells, fibroblasts, neutrophils, and macrophages [10, 21, 27]. Consistent with this, 
there was no significant difference in Gas6 mRNA expression between isolated 
intestinal epithelial cells and stromal monocytes, and immunostaining against Gas6 was 
ubiquitous in both residual epithelial cells and stromal inflammatory cells in the 
DSS-treated Gas6+/+ mice (data not shown). These data suggest that both epithelial and 
infiltrating stromal cells produce Gas6. To determine the cellular sources of Gas6 that 
suppressed DSS-induced colitis, we performed BM transplantations using Gas6+/+ and 
Gas6–/– mice. Under physiological conditions, there was no evident difference in any 
mice undergoing BM transplantation (data not shown). After administration of 2.5% 
DSS for 7 days, the Gas6–/– mice transplanted with Gas6–/– marrow exhibited the most 
severe colitis, based on histological damage scores and weight loss (Supplementary 
Figure 3A-C). The Gas6+/+ mice transplanted with Gas6+/+ marrow showed the least 
severe colitis. Gas6–/– mice transplanted with Gas6+/+ marrow and Gas6+/+ mice 
transplanted with Gas6–/– marrow exhibited nearly the same degree of moderately 
severe colitis. Furthermore, the mRNA expression of inflammatory cytokines, such as 
TNF- and CXCL1, was altered in parallel with the histological changes 
(Supplementary Figure 3D). Thus, Gas6 from both epithelial cells and BM-derived cells 
may contribute to suppression of DSS-induced mouse colitis. 
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Gas6 deficiency enhanced intestinal tumorigenesis in the ApcMin mice 
 Most human colorectal cancers develop in a ‘multistep’ manner without obvious 
inflammation. Using ApcMin mice, we examined the role of Gas6 in multistep intestinal 
tumorigenesis. Nontumorous intestinal mucosa in the ApcMin Gas6–/– mice does not 
show histologically detectable inflammation as well as that in the simple Gas6–/– mice 
(data not shown). The number of polyps in the small intestine and colon of the ApcMin 
Gas6–/– mice was significantly greater than that in the ApcMin Gas6+/+ mice (Figure 5A 
and B, and Supplementary Figure 4). PCNA mRNA expression was significantly 
elevated in the intestinal polyps of the ApcMin Gas6–/– mice compared with that in the 
intestinal polyps of the ApcMin Gas6+/+ mice (Figure 5C). Production of inflammatory 
cytokines, such as TNF-, CXCL1, and CCL2 was significantly increased in the 
intestinal polyps of ApcMin Gas6–/– mice (Figure 5C). NFB was significantly activated 
in the intestinal polyps of the ApcMin Gas6–/– mice (Figure 5D). The mRNA expression 
of c-Myc and Cox2 (Ptgs2), a downstream target of NFB, was also significantly 
upregulated in the intestinal polyps of the ApcMin Gas6–/– mice (Figure 5C). Consistently, 
the ApcMin Gas6–/– mice showed more severe anemia (Figure 5E) with significantly 
shorter survival compared with the ApcMin Gas6+/+ mice (P < 0.001; Figure 5F). Thus, 
Gas6 suppresses multistep tumorigenesis as well as colitis-associated tumorigenesis in 
mouse intestines. 
 
Elevated Gas6 was associated with better prognosis in advanced colorectal cancer 
patients 
 15 
 To determine the role of Gas6 in human colorectal cancer, we immunostained 
surgically resected specimens of 62 colorectal cancer patients (Figure 6A), and 
compared patient survival. Higher expression of Gas6 in cancer tissues was associated 
with better survival in stages III (Figure 6B, left) and IV (Figure 6B, right, P < 0.05), 
and overall advanced colorectal cancer patients (Figure 6C, P < 0.05). Similar to murine 
models, increased expression of Gas6 was also significantly associated with decreased 
infiltration by CD45-positive leukocytes and lower expression of TNF- 
(Supplementary Table 3). These results suggest that Gas6 plays an inhibitory role in 




 Previous studies have suggested that Gas6 promotes cancer cell progression in vitro 
[15, 16]. A previous study demonstrated that Gas6 produced from BM-derived cells 
enhances proliferation of subcutaneously transplanted murine colon cancer cells lacking 
Gas6 [21]. In this study, we also observed that Gas6 weakly, but significantly, enhances 
proliferation of human cancer cell lines. Importantly, these effects of Gas6 are exerted at 
cellular levels. The role of Gas6 should be complicated during in vivo intestinal 
tumorigenesis, because the intestines are inhabited by a vast population of microbes that 
play important roles in intestinal tumorigenesis [1-4]. In line with previous studies [5, 6, 
12, 13], we also showed that Gas6 suppressed innate immune responses of a human 
monocyte cell line. 
 We analyzed AOM/DSS intestinal tumor formation model, and revealed that the 
number of polyps in the Gas6–/– mice was greater than that in the Gas6+/+ mice. 
Persistent colitis is a well-known risk factor for the progression of colonic tumors both 
in humans and mice [24, 25]. In our study, because the DSS-treated Gas6–/– mice 
exhibited more severe colitis than the DSS-treated Gas6+/+ mice, it can be reasoned that 
the absence of Gas6 and its anti-inflammatory activity was responsible for the increased 
number of polyps in the AOM/DSS-treated Gas6–/– mice. Thus, in contrast to its in vitro 
behavior, the property of Gas6 to inhibit inflammatory cytokine production [5, 6, 12, 
13], appears to exert an important negative effect on mouse intestinal tumorigenesis. 
 In monocyte lineages, Gas6/TAM signaling suppresses NFB activation and 
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inflammation through the induction of Socs1/3 [5, 6]. Our BM transplantation 
experiments showed that Gas6 from both epithelial cells and BM-derived cells 
contributed to the suppression of DSS-induced mouse colitis. This is in line with the 
fact that Gas6 is a secretory protein, and the degree of suppression of colitis appeared to 
be determined by local Gas6 dosage. Because BM transplantation could not directly 
indicate the target cells of Gas6, we speculated that cells in which NFB and Soxs1/3 
are activated could be the target of Gas6/TAM signaling. In our in vivo study, intense 
immunostaining of phosphorylated p65 and Socs3 was observed in the stromal 
infiltrating cells rather than the epithelial cells in the DSS-treated inflamed mouse colon. 
Phosphorylation of p65 and mRNA expression of Socs1/3 were significantly lower in 
the absence of Gas6. Although not directly, these in vivo results suggest that the 
predominant target of Gas6 was stromal infiltrating cells rather than epithelial cells, and 
that Gas6 inhibits intestinal inflammation in DSS-induced colitis by suppressing 
immune responses of stromal monocyte lineages (e.g., macrophages). These results also 
support the notion that the weak growth-promoting effect of Gas6 on epithelial cells 
may be overcome by strong immune suppressive effect of Gas6 on monocyte lineages 
during in vivo intestinal tumorigenesis. 
 It should be noted that similar to the AOM/DSS colitis mice, in the ApcMin mouse 
model in our study, the number of polyps in the Gas6–/– mice was greater than that in the 
Gas6+/+ mice, thereby resulting in significantly severe anemia and shorter survival. In 
contrast to the AOM/DSS colitis mouse, the ApcMin mouse is not characterized by the 
presence of obvious intestinal inflammation. However, polyps from both AOM/DSS and 
 18 
ApcMin mice are exposed to LPS-producing luminal bacteria. Lack of TLR signaling or 
microbes suppresses ApcMin mouse intestinal tumorigenesis [3, 4]. Furthermore, lack of 
TNF-, a key inflammatory cytokine that induces NFB activation, significantly 
reduces intestinal polyp formation in ApcMin mice [25]. In our study, the activity of 
NFB, a downstream target of TLR signaling, and TNF- mRNA levels were 
significantly higher in the Gas6–/– mice than in the Gas6+/+ mice with either AOM/DSS 
treatment or ApcMin genotype. Consistent with these data, Cox2 (Ptgs2), a key 
tumor-promoting factor regulated by NFB, was also significantly elevated in the 
Gas6–/– mice. Therefore, activation of the TLR/TNF--NFB-Cox2 pathways appears 
to be one of the important events that promote intestinal tumorigenesis in the absence of 
Gas6 in both AOM/DSS-treated and ApcMin mouse models. 
 In humans, we found that higher expression of Gas6 in the cancer tissues was 
associated with longer survival and a milder local inflammatory responses in colorectal 
cancer patients. These data are consistent with our murine models and with a previous 
study showing that high Gas6 expression was associated with better prognosis of renal 
cancer patients [18]. However, a recent report showed that the activation of AXL is 
associated with the resistance to EGFR-targeted therapy in lung cancer [16]. In addition, 
it is important to note that warfarin, which has an inhibitory effect on Gas6 activity by 
blocking vitamin K-dependent -glutamyl carboxylation, is widely used as an 
anticoagulant. As for the association between warfarin use and the prognosis of cancer 
patients, a recent large cohort study showed that the effect of warfarin on patient 
survival was identical to that of placebo in gastrointestinal cancers [28]. Thus, the role 
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of Gas6 and related factors appears complex, and further studies are required to 
determine the comprehensive role of Gas6 and TAM receptors in colorectal cancer 
patients. 
 In conclusion, we demonstrated that Gas6 has an inhibitory effect on intestinal 
tumorigenesis in vivo. Although additional clinical studies are required to clarify the 
roles of Gas6 in human colorectal cancers, our results may provide clues for developing 
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Figure 1. Administration of GAS6 enhanced proliferation of colon epithelial cells and 
suppressed immune reactions of macrophages. 
(A) Western blotting showed protein expression of TAM receptors in SW480 and HT29, 
human colon cancer cell lines, and THP-1, a human macrophage cell line. ß-ACTIN 
was shown as a control. 
(B) SW480 and HT29 cells were incubated in a serum-free medium containing vitamin 
K (0.5 µM) with or without recombinant human GAS6 protein. After 24-hour 
incubation, cellular proliferation was measured using the MTS assay (mean ± SD, n = 5 
each). *P < 0.05. 
(C and D) THP-1 cells pretreated with PMA (100 nM) were administered LPS (100 
ng/ml) with or without recombinant GAS6 (0.5 nM). After 2 hours, RNA was extracted 
and mRNA expression was evaluated by qRT-PCR (mean ± SD, n = 5 each). *P < 0.05 
(E) Representative immunostainings of nuclear accumulated phosphorylated (p)-p65 
after 2-hour incubation with and without 0.5 nM recombinant GAS6 in PMA-stimulated 
(left) and PMA/LPS-stimulated (right) THP-1 cells. Bars, 10µm. 
(F) Percentages p-p65-immunostained THP-1 cells were evaluated by immunostainings 
for p-p65 (mean ± SD, n = 5 each). *P < 0.05 
 
Figure 2. Deficiency of Gas6 enhanced mouse AOM/DSS-induced colonic polyp 
formation. 
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(A) Representative histology of the colonic polyp in Gas6+/+ and Gas6–/– mice after the 
administration of AOM/DSS. Dotted lines indicate polyp margins. Bars, 200µm. 
(B) Total polyp numbers (left) and those in indicated size fractions (right) in Gas6+/+ 
and Gas6–/– mice after the administration of AOM/DSS (mean ± SD/mouse, n = 10 
each). *P < 0.05 
(C, E, and G) RNA was extracted from colonic polyps, and mRNA expression was 
evaluated by qRT-PCR in AOM/DSS-treated Gas6+/+ and Gas6–/– mice (mean ± SD, n = 
10 mice each). *P < 0.05 
(D) The numbers of Gr-1-positive and F4/80-positive cells in 400 high power field in 
AOM/DSS-treated Gas6+/+ and Gas6–/– mouse polyps (mean ± SD, n = 10 each). *P < 
0.05 
(F) Nuclear protein was extracted from AOM/DSS-treated Gas6+/+ and Gas6–/– mouse 
polyps, and phosphorylation of p65 protein was quantified by ELISA (mean ± SD, n = 5 
each). *P < 0.05 
(H) There was a significant difference of survival between AOM/DSS-treated Gas6+/+ 
and Gas6–/– mice (n = 20 each, P < 0.01). 
 
Figure 3. Deficiency of Gas6 caused severe DSS-induced mouse colitis. 
(A) Representative histology of DSS-treated Gas6+/+ and Gas6–/– moue colon. Note that 
crypt-like structures (*) were barely preserved in Gas6+/+ mouse colon. Bars, 50µm. 
(B) Histological damage scores (left) and body weight lossees (right) in DSS-treated 
Gas6+/+ and Gas6–/– mice (mean ± SD, n = 10 each). Body weight before the 
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administration of DSS was defined as 100%. *P < 0.05 
(C) Top; The numbers of Gr-1-positive and F4/80-positive cells in DSS-treated Gas6+/+ 
(white bar) and Gas6–/– (black bar) mouse colon (mean number/400 high power field ± 
SD, n = 10 each). *P < 0.05 Bottom; Immunostainings for Gr-1 and F4/80 in 
DSS-treated Gas6+/+ and Gas6–/– mouse colons. Bars, 50µm. 
(D) RNA was extracted from colonic tissues in DSS-treated Gas6+/+ (white bar) and 
Gas6–/– (black bar) mice, and mRNA expression of each factor was evaluated by 
qRT-PCR in colonic tissues of DSS-treated Gas6+/+ and Gas6–/– mice (mean ± SD, n = 
10 each). *P < 0.05 
 
Figure 4. Target molecules of Gas6 were activated in the stroma of DSS-induced mouse 
colitis. 
(A) RNA was extracted from colonic tissues in DSS-treated Gas6+/+ (white bar) and 
Gas6–/– (black bar) mice, and mRNA expression of each factor was evaluated by 
qRT-PCR in colonic tissues of DSS-treated Gas6+/+ and Gas6–/– mice (mean ± SD, n = 
10 each). *P < 0.05 
(B) Nuclear protein was extracted from colonic tissues in DSS-treated Gas6+/+ and 
Gas6–/– mice, and phosphorylation of p65 protein was determined by ELISA (mean ± 
SD, n = 5 each). *P < 0.05 
(C) Representative immunostainings against Socs3 and phosphorylated (p)-p65 in 
DSS-treated Gas6+/+ and Gas6–/– mouse colon. Socs3 and p-p65 immunostainings were 
observed in epithelial cells in non-inflamed ascending colon (arrowheads). However, 
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Socs3 and p-p65 were primarily expressed in the stromal infiltrating mononuclear cells 
in inflamed rectum. Bars, 20µm. 
 
Figure 5. Deficiency of Gas6 promoted intestinal polyp formation in ApcMin mice. 
(A) Numbers of the intestinal polyps in ApcMin Gas6+/+ and ApcMin Gas6–/– mice (mean 
± SD/mouse, n = 10 each). *P < 0.05 
(B) Numbers of the intestinal polyps in indicated size fractions of ApcMin Gas6+/+ and 
ApcMin Gas6-/- mice (mean ± SD/mouse, n = 10 each). *P < 0.05 
(C) RNA was extracted from small intestinal polyps in ApcMin Gas6+/+ and ApcMin 
Gas6–/– mice, and mRNA expression was evaluated by qRT-PCR (mean ± SD, n = 10 
each). *P < 0.05 
(D) Nuclear protein was extracted from small intestinal polyps in ApcMin Gas6+/+ and 
ApcMin Gas6–/– mice, and phosphorylation of p65 protein was quantified by ELISA 
(mean ± SD, n = 5 each). *P < 0.05 
(E) Hemoglobin concentrations in ApcMin Gas6+/+ and ApcMin Gas6–/– mice were 
depicted at the indicated time points (mean ± SD/mouse, n = 5 each, *P < 0.05). 
(F) There was a significant difference of survival between ApcMin Gas6+/+ and ApcMin 
Gas6–/– mice (P < 0.001).  
 
Figure 6. Elevated Gas6 was associated with better prognosis in advanced colorectal 
cancer patients. 
(A) Representative immunostaining against Gas6 in human colorectal cancer patients. 
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High expression of Gas6 was observed in cancer cells (Case 1 and 2) and stromal cells 
(Case 2). Bars, 50µm. 
(B) Kaplan-Meier analyses showing that higher expression of Gas6 protein were 
associated with better survival in stage III (left) and IV (right, P < 0.05) colorectal 
cancer patients. 
(C) Kaplan-Meier analysis showing that higher expression of Gas6 protein was 
significantly associated with better survival in stage III/IV colorectal cancer patients (P 
< 0.05). 
 
Supplementary Figure 1. Schema of drug treatment schedule. 
(A) To analyze the colitis-associated intestinal tumorigenesis, AOM (12 mg/kg body 
weight) was administered intraperitoneally at the beginning of drug treatment. 
Thereafter, 2.0% DSS was administered ad libitum for 5 days 3 times. 
(B) To analyze the severity of colitis, 2.5% DSS was administered ad libitum for 7 days. 
 
Supplementary Figure 2. Gas6 from both epithelial cells and bone marrow (BM) 
derived cells contributed to suppress DSS-induced mouse colitis. 
(A) Representative histology of DSS-treated each BM-transplanted moue colon. Bars, 
50µm. 
(B and C) Histological damage scores (B) and body weight losses (C) in DSS-treated 
BM-transplanted mice (mean ± SD, n = 5 each). Body weight before the administration 
of DSS was defined as 100% (C). Only Gas6–/– mice transplanted with Gas6–/– marrow 
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showed a significant change compared to Gas6+/+ mice transplanted with Gas6+/+ 
marrow. *P < 0.05 
(D) RNA was extracted from colonic tissues of DSS-treated BM-transplanted mice, and 
mRNA expression of each cytokine was evaluated by qRT-PCR (mean ± SD, n = 5 
each). *P < 0.05 
 
Supplementary Figure 3. Intestinal polyp formation in ApcMin Gas6+/+ and ApcMin 
Gas6–/– mice. 
(A) Representative images of polyps in ApcMin Gas6+/+ and ApcMin Gas6–/– mouse small 
intestines. Dotted lines indicate polyp margins. Bars, 100µm. 
(B) Representative images of polyps in ApcMin Gas6+/+ and ApcMin Gas6–/– mouse 
colons. Dotted lines indicate polyp margins. Bars, 100µm. 









